Principal Financial Group Inc Sage Therapeutics, Inc. Transaction History

Principal Financial Group Inc

$160 Billion
Q2 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$18.62 - $26.95 $6,554 - $9,486	352 Added 2.58%	13,976 $261,000
Q4 2023 Feb 07, 2024	BUY	$17.1 - $22.26 $256 - $333	15 Added 0.11%	13,624 $295,000
Q3 2023 Nov 02, 2023	SELL	$16.75 - $48.98 $2,311 - $6,759	-138 Reduced 1.0%	13,609 $280,000
Q2 2023 Aug 07, 2023	SELL	$40.65 - $59.54 $27,804 - $40,725	-684 Reduced 4.74%	13,747 $646,000
Q1 2023 May 09, 2023	BUY	$37.27 - $46.57 $80,316 - $100,358	2,155 Added 17.55%	14,431 $605,000
Q4 2022 Feb 09, 2023	BUY	$32.2 - $43.61 $2,157 - $2,921	67 Added 0.55%	12,276 $468,000
Q3 2022 Nov 09, 2022	BUY	$32.28 - $43.27 $92,385 - $123,838	2,862 Added 30.62%	12,209 $478,000
Q2 2022 Aug 10, 2022	BUY	$27.52 - $37.99 $68,304 - $94,291	2,482 Added 36.15%	9,347 $302,000
Q1 2022 May 09, 2022	SELL	$30.71 - $45.71 $5,374 - $7,999	-175 Reduced 2.49%	6,865 $227,000
Q4 2021 Feb 09, 2022	SELL	$37.06 - $47.11 $181,705 - $230,980	-4,903 Reduced 41.05%	7,040 $299,000
Q3 2021 Nov 09, 2021	SELL	$40.26 - $57.37 $229,280 - $326,722	-5,695 Reduced 32.29%	11,943 $529,000
Q2 2021 Aug 10, 2021	BUY	$54.88 - $79.29 $119,418 - $172,535	2,176 Added 14.07%	17,638 $1 Million
Q1 2021 May 10, 2021	BUY	$70.65 - $96.76 $103,431 - $141,656	1,464 Added 10.46%	15,462 $1.16 Million
Q4 2020 Feb 08, 2021	SELL	$58.41 - $89.06 $46,728 - $71,248	-800 Reduced 5.41%	13,998 $1.21 Million
Q3 2020 Nov 06, 2020	BUY	$41.13 - $62.45 $136,058 - $206,584	3,308 Added 28.79%	14,798 $904,000
Q2 2020 Aug 05, 2020	BUY	$25.95 - $43.15 $91,395 - $151,974	3,522 Added 44.2%	11,490 $478,000
Q1 2020 May 12, 2020	SELL	$26.15 - $77.24 $135,352 - $399,794	-5,176 Reduced 39.38%	7,968 $229,000
Q4 2019 Feb 05, 2020	SELL	$60.18 - $154.77 $16,308 - $41,942	-271 Reduced 2.02%	13,144 $949,000
Q3 2019 Nov 13, 2019	SELL	$140.29 - $189.96 $76,177 - $103,148	-543 Reduced 3.89%	13,415 $1.88 Million
Q2 2019 Aug 12, 2019	BUY	$157.85 - $183.09 $169,846 - $197,004	1,076 Added 8.35%	13,958 $2.56 Million
Q1 2019 May 10, 2019	SELL	$89.33 - $163.65 $921,885 - $1.69 Million	-10,320 Reduced 44.48%	12,882 $2.05 Million
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $19,911 - $33,949	243 Added 1.06%	23,202 $2.22 Million
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $119,050 - $145,712	862 Added 3.9%	22,959 $3.24 Million
Q2 2018 Aug 13, 2018	BUY	$140.36 - $175.76 $1.36 Million - $1.7 Million	9,691 Added 78.12%	22,097 $0
Q1 2018 May 14, 2018	BUY	$152.15 - $192.33 $58,121 - $73,470	382 Added 3.18%	12,406 $2 Million
Q4 2017 Feb 13, 2018	BUY	$60.72 - $167.34 $404,455 - $1.11 Million	6,661 Added 124.2%	12,024 $1.98 Million
Q3 2017 Nov 02, 2017	BUY	$61.4 - $88.52 $329,288 - $474,732	5,363	5,363 $334,000

Others Institutions Holding SAGE

# of Institutions

218

Shares Held

48.2M

Call Options Held

854K

Put Options Held

195K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $395M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account